We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What issues? They are flying off the shelves in Boots and over the Amazon internet counter.
What data do you have to say there's an issue? Can you share?
Here is data to the contrary...
Https://hbw.pharmaintelligence.informa.com/RS153806/A-Phenomenon--Futuras-Eroxon-ED-Gel-Gets-Off-To-Flying-Start-In-The-UK
Buildworker - You have literally echoed my thoughts. I have long felt that the competition was always going to be the generics and therefore the Eroxon pricing should have reflected those parameters. Yes, OTC availability, efficacy levels, lack of significant side effects give Eroxon the edge, However, multiple use scenario and launching of a new product, should have formed part of the pricing equation. Pricing can always be reviewed when volumes materialize - supply/demand (depending upon who is in overall control of pricing)
We are where we are now. I am sure the US deal will address these issues.
I was in some motorway services last week and there was an advert for prostate issues (I think?) above each urinal. I've seen similar posters on "ED advice" in the past and wonder whether a similar campaign for Eroxon would be worthwhile? It's certainly the target audience we're looking for!
Surely advertising on the London tube or any other public transport venue will give the best “bang for buck” )rather than very brief TV advertising) as well as a lingering captive audience – any thoughts or is it against advertising standards?
Last thing I want to do is deramp, as I have a lot to lose. I’m putting myself in the position of a customer and what would make me want to always have this product in my bedside cabinet.
Efficacy, price and ease of use. For what it’s worth, just prior to FDA approval I put another £10k into FUM, a the same time as £10k into THG. FUM currently showing 24% gain, THG 34% gain..
Https://hbw.pharmaintelligence.informa.com/RS153806/A-Phenomenon--Futuras-Eroxon-ED-Gel-Gets-Off-To-Flying-Start-In-The-UK
Sales up faster than an Eroxon induced erection!
Don't listen to the derampers. GLA.
I read Boots can't stock the shelves fast enough to keep up with sales demand.
Can speak for instore sale but have been looking online and there maybe difference between "added to basket "and numbers sold. The numbers sold and " minutes since last sale " doesn't come up often at all but when it does it mostly 100Plus sales in last 24hrs ,,,,and yes its been that way for last week except 1 day which said "93 sold in last 24 hrs"
Obviously who know what tricks Boots IT dept have
Thanks for your input Jet. Why do you feel you couldn’t use a dispenser?
Re: Amazon sales, my concern is how many of these will become repeat customers. I suspect the majority will try it once only, but conclude not enough bang fo their buck and too tedious to use. At £6+ a dose, your focus is more likely to be to ensure you squeeze every last drop out off the tiny tube to get your money’s worth, expecting something miraculous to happen. I suggest it should be be in a simple to use and easily accessible pump action dispenser, which allows you to keep the spontaneity of the moment, and at a price which encourages you to persevere.
Fair comment Buildworker although they will not be able to use a dispenser and what price do you put on a pain, reaction free remedy if it works. Trust me there must have been plenty of discussions around price and Coopers I am sure would have had a big say in this. I’d say the big issue is guys trying it once and giving up on it if it doesn’t work, that is what FUM somehow need to address.
Early days but the update we received on the webcast was extremely positive, I have faith in management and Coopers.
Maybe sales have been transferred to Amazon. Theirs have gone from 1000 per month 7000 per month!
I’ve been keeping tabs on their website and for the first few weeks post launch you could see 100+ sold in the last 24hrs. Not sure if that is a rolling 24 hour period or a daily 24 hours. Also product flying off shelves in store. Look now and there are barely 12 added to basket in the last 24 hours and loads of stock in store.. In other words a 90% fall. Probably to be expected to some extent, but I still believe the price point is too high and the packaging is not conducive to easy use. These can be addressed by FUM and Coopers, to generate much greater ongoing sales, albeit at slightly reduced margins.
Have sales at Boots really "fallen off a cliff"?
I would further comment that I hope FUM and partners are taking note of the feedback to date and quickly realign their strategy before US launch, as it’s clear from Boots website that sales have fallen off a cliff. Pitched at the right price and in an easy to apply dispenser can still allow Eroxon to fly, as both an ED treatment and a recreational boost.
IMO FUM have got this wrong in a number of ways. Firstly, pricing strategy is way off. They’ve tried to align it with the likes of Viagra and Cialis, which when introduced were novel treatments. However, the price point for their generic equivalents is now as low as £1 per dose, so Eroxon is way out of step. Furthermore, when you look at the ingredients, you don’t need degree in chemistry to understand these are common base ingredients used in a multitude of skin care and hygiene products, so it feels overpriced. The problem with the high price tag is that it raises expectations to an unreasonably high level and amplifies the dissatisfaction feeling when you don’t get the response you hoped for. Hence so many negative reviews.
It’s stated that the efficacy improves with further use, but the problem with this is that the initial response and dose price has already set a seed of failure in the minds of users - just another ‘miracle cure’ con. I think Eroxon, as a novel treatment, can carry a small premium, but £2 per dose would achieve greater acceptance and willingness to persevere.
Secondly, packaging. In order to justify the price tag and presumably give the product some kind of upmarket medical feel, it’s presented in tiny individual dose tubes. This makes it a cumbersome and fiddly process to apply the product in you moment of passion and all spontaneity is lost. IMO, it should be presented in a high quality, premium feel, multi dose pump action dispenser. Something that can be kept bedside and ready to go and encourage users to slap it on. As there’s no active drug, there’s no issue with overdosing.
Perhaps a change of mentality would make things a little less stressful. Instead of trying to second guess the next set of news to make a few quid on a trade, why not reflect upon the future potential here and relax in the knowledge that multiple new commercial deals will be signed and announced in coming months as well as revenue figures and more granularity in terms of repeat purchases and effectiveness of distribution channels etc. This is what will move the share price onto a different level but of course these things actually take a little time and in today’s world of instant gratification ( Eroxon can help in this regard) a few weeks is as long as some people are prepared to wait for their pot of gold.
I really have no idea and as said previously nor will anyone else. Let's just hope it's days rather than weeks or months.
Thanks Surfie, I thought it might be better guessing at the guidance rather than the chemical composition for a change of topic 😅
Do you think it's weeks away? Months?
I'm hopeful it's in Q3 but have no idea, hence the question.
I agree an email won't work.
"When an a deal for sales in America will be signed and ready to go"?
Really Banzai? How do you think anyone on here is going to know that? Try emailing the company and asking them. If you get a reply (which I doubt) post it on here.
When an a deal for sales in America will be signed and ready to go?
Martin - There is no magic ingredient other than;
"..what makes Eroxon unique is the way these ingredients are combined, using a proprietary technology."
As we are debating, not the patent but an extension of it, suggests that this formulation is not only patent-able it has been successfully patented. FUM are confident of the gaining an extension.
Many thanks for your detailed reply. Can you help me understand what is unique about the Eroxon formula.The ingredients are all quite common in other formulations e.g. hand sanitiser.What is it that will justify the granting of a patent and therefore preventing other companies copying the product. I know it was stated at the investor presentation that FUM are confident of securing a patent extension.But I would love to have it explained what is unique about Eroxon.
Martinelwick - I have commented on this before. There is a lot of misinformation and frankly lazy journalism out there. A number of sources are misleadingly suggesting that Eroxon contains things which it absolutely does not - usually the reference is to the GTN which was in the original FUM product but is not in the current product. You mention Alprostadil, which is a vasodilator and has similar effects to GTN. The product which is now Eroxon was originally used as a comparator in a clinical trial which was testing the efficacy of the original GTN based product. As this product worked just as well, the GTN ( which has side effects) was dropped and Eroxon only contains the ingredients that others have listed - ingredients which cause the heating and cooling effect and increased blood flow without the need for traditional drugs such as GTN to achieve that increased blood flow. Even a website for GP education and information ( GP notebook) still has wrong information about this, even though it was reviewed as supposedly accurate only last month.
I see jonnybutler/NicName has raised his ugly head again! He pops in every now and again to drop one of his pointless (and usually wrong) stock bashing nuggets!